轻度治疗性低温对心脏骤停后综合征患者的疗效因早期CT缺氧性脑病表现而异
该回顾性研究纳入129例心脏骤停后综合征患者,均在开始轻度治疗性低温(34°C)或常温治疗(35°C或36°C)前接受脑CT检查,按有无缺氧性脑病征象及治疗方式分为4组。无缺氧性脑病征象组中,轻度治疗性低温组30天良好神经功能结局(大脑功能分类评分≤2)比例为68.9%(42/61),常温治疗组为36.1%(13/36),差异有统计学意义(p=.003);有缺氧性脑病征象组中,轻度治疗性低温组为7.4%(2/27),常温治疗组为20.0%(1/5),差异无统计学意义(p=.410);两变量交互效应有统计学意义(pinteraction=0.002)。无缺氧性脑病征象组中,轻度治疗性低温较常温治疗与更高良好结局比值比相关(OR 6.80,95%CI 1.19-38.96,p=.031)。结论认为轻度治疗性低温的效应取决于早期CT有无缺氧性脑病征象。
要点
- 早期脑CT无缺氧性脑病征象的心脏骤停后综合征患者,轻度治疗性低温(34°C)组30天良好神经功能结局为68.9%(42/61),常温治疗(35°C或36°C)组为36.1%(13/36)(p=.003)。
- 无缺氧性脑病征象组中,轻度治疗性低温较常温治疗与更高良好结局比值比相关(OR 6.80,95%CI 1.19-38.96,p=.031)。
- 早期脑CT有缺氧性脑病征象者,轻度治疗性低温组良好结局为7.4%(2/27),常温治疗组为20.0%(1/5),差异无统计学意义(p=.410)。
- 缺氧性脑病征象与治疗方式对良好神经功能结局存在交互效应(pinteraction=0.002),提示轻度治疗性低温的效应因早期CT有无缺氧性脑病征象而异。
- 良好神经功能结局定义为30天时大脑功能分类评分≤2。
适用人群与场景
- 心脏骤停后综合征患者,均在开始轻度治疗性低温或常温治疗前接受脑CT检查。
诊断标准与关键阈值
- 良好神经功能结局定义为30天时大脑功能分类评分≤2。
- 按早期脑CT有无缺氧性脑病征象及治疗方式分为HE(-)/MTH、HE(-)/NT、HE(+)/MTH、HE(+)/NT四组。
处置流程与药物剂量
- 轻度治疗性低温:目标温度34°C。
- 常温治疗:目标温度35°C或36°C。
研究设计与关键结果
- 回顾性研究,共纳入129例心脏骤停后综合征患者,比较轻度治疗性低温(34°C)与常温治疗(35°C或36°C)的神经功能结局。
- 无缺氧性脑病征象组:轻度治疗性低温组30天良好结局68.9%(42/61)vs 常温治疗组36.1%(13/36)(p=.003)。
- 有缺氧性脑病征象组:轻度治疗性低温组良好结局7.4%(2/27)vs 常温治疗组20.0%(1/5)(p=.410)。
- 交互效应有统计学意义(pinteraction=0.002)。
- 无缺氧性脑病征象组中,轻度治疗性低温较常温治疗与更高良好结局比值比相关(OR 6.80,95%CI 1.19-38.96,p=.031)。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,心脏骤停后综合征患者轻度治疗性低温的效应取决于早期脑CT有无缺氧性脑病征象。
- 早期脑CT无缺氧性脑病征象的患者,轻度治疗性低温(34°C)较常温治疗(35°C或36°C)与更高的30天良好神经功能结局相关(OR 6.80,95%CI 1.19-38.96)。
- 早期脑CT有缺氧性脑病征象的患者,轻度治疗性低温组与常温治疗组良好神经功能结局无显著差异(p=.410)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: The aim of this study was to evaluate the differential effects of mild therapeutic hypothermia (MTH) in post-cardiac arrest syndrome (PCAS) patients depending on the presence/absence of hypoxic encephalopathy (HE) in the early brain CT images obtained before the initiation of MTH.
METHODS: We conducted a retrospective review of the data of a total of 129 patients with PCAS who were treated by MTH (34 °C) or normothermia treatment (NT) (35 °C or 36 °C), and had undergone brain CT examination prior to the initiation of these treatments. We divided the subjects into 4 groups, namely, the HE(-)/MTH, HE(-)/NT, HE(+)/MTH, and HE(+)/NT groups, for evaluating the interaction effect between the two variables. Then, we compared the neurological outcomes between the HE(-)/MTH and HE(-)/NT groups by multivariate logistic analysis. Good outcome was defined as a Cerebral Performance Category score of ≤2 at 30 days.
RESULTS: The percentages of subjects with a good outcome in the HE(-)/MTH and HE(-)/NT group were 68.9% (42/61) and 36.1% (13/36), respectively (p = .003), while those in the HE(+)/MTH and HE(+)/NT groups were lower, at 7.4% (2/27) and 20.0% (1/5), respectively (p = .410), suggesting a statistically significant interaction effect between the two variables (pinteraction = 0.002). In the HE(-) group, MTH was associated with a higher odds ratio of a good outcome as compared to NT (OR 6.80, 95% CI 1.19-38.96, p = .031).
CONCLUSIONS: The effect of MTH in patients with PCAS differed depending on the presence/absence of evidence of HE on the early CT images.
参考来源
- Nishikimi M, Ogura T, Nishida K, et al. Differential effect of mild therapeutic hypothermia depending on the findings of hypoxic encephalopathy on early CT images in patients with post-cardiac arrest syndrome. Resuscitation. 2018. PMID: 29698752. doi:10.1016/j.resuscitation.2018.04.029
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。